The AHA and other plaintiffs late Friday asked a federal district judge to set a firm June deadline for the Department of Health and Human Services to propose remedies to the nearly 30 percent cuts to Medicare payments affecting certain hospitals that participate in the 340B Drug Pricing Program. The judge last week had set an Aug. 5 deadline for the remedies.
 
In the filing, the plaintiffs said “it is important that the Court require HHS to propose its remedy by the end of June 2019 or shortly thereafter, since unless there is a Court order on the remedy in this case this summer, Defendants may issue a 2020 OPPS [outpatient prospective payment system] rule reducing reimbursements for 340B drugs by nearly 30 percent in violation of law, just as they did in 2018 and 2019.” While the final OPPS rule generally is issued by the Centers for Medicare & Medicaid Services in November, the agency typically issues its proposal in late July. 
 
A federal district court judge last week said HHS would get "first crack at crafting appropriate remedial measures" to the cuts, and also held that, like the 2018 cuts, the 2019 cuts to 340B hospitals were unlawful.
 

Related News Articles

Headline
Former AHA Board Member John “Jack” J. Lynch III and AHA President and CEO Rick Pollack have been announced as the 2026 recipients of the American College of…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Blog
Public
Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4…
Headline
The AHA, the Maine Hospital Association and four safety-net health systems from across the country Dec. 1 filed a lawsuit in the U.S. District…
Chairperson's File
Public
For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription…
Chairperson's File
Public
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…